

Effect of perioperative complications after endovascular therapy in patients with peripheral artery disease due to femoropopliteal lesions

Kei Sato, MD,^{a,b} Osamu Iida, MD,^c Mitsuyoshi Takahara, MD, PhD,^d Yoshimitsu Soga, MD,^c Kenji Suzuki, MD,^f Takashi Tanigawa, MD, PhD,^g Masaaki Ito, MD, PhD,^b and Masaaki Uematsu, MD, PhD,^c *Fuchu, Tsu, Amagasaki, Suita, Kitakyushu, Sendai, and Matsusaka, Japan*

Objective: Despite wide use, high initial success, and acceptable durability of endovascular therapy (EVT) for femoropopliteal (FP) lesions, the frequency of 30-day perioperative complications (POCs) and their effect on clinical outcomes have not been systematically evaluated, which is the subject of this study.

Methods: We used a multicenter database of 2145 consecutive patients (70% male; overall mean age, 73 ± 9 years) who successfully underwent EVT for FP lesions to investigate independent predictors of POCs (logistic regression analysis) and effect of POCs on prognostic outcomes (Cox proportional regression).

Results: POCs were observed in 209 patients (10%). In multivariate logistic regression analysis, body mass index <18.5 kg/m², critical limb ischemia, and TransAtlantic Inter-Society Consensus for the Management of Peripheral Arterial Disease class D lesions were independently associated with POCs (adjusted odds ratios [95% confidence intervals], 2.0 [1.3-2.9], 2.5 [1.9-3.3], and 1.6 [1.2-2.1], respectively). After risk stratification of POCs according to the number of these risk factors, the incidence of POCs was higher in the groups with higher scores. Follow-up for >30 days (mean, 2.3 ± 1.8 years) was available for 2079 of 2145 patients. A Cox hazard regression model adjusted for baseline clinical characteristics showed POCs were negatively and independently associated with future occurrence of major adverse limb events (defined as major amputation and major reintervention) or death (hazard ratio [95% confidence interval], 1.6 [1.2-2.1]; $P < .05$).

Conclusions: Body mass index <18.5 kg/m², critical limb ischemia, and TransAtlantic Inter-Society Consensus for the Management of Peripheral Arterial Disease class D lesion were positively associated with POCs after EVT for FP lesions. The occurrence of POCs may adversely affect clinical outcomes in the chronic phase. (*J Vasc Surg* 2015;61:1272-7.)

Femoropopliteal (FP) lesions are found in 60% to 70% of patients with symptomatic peripheral artery disease.¹⁻³ Endovascular therapy (EVT) has proven efficacious and safe in treatment of TransAtlantic Inter-Society Consensus (TASC) II A-B localized atherosclerotic FP lesions, for which it is considered first-line therapy because of its less invasive nature and high initial technical success.⁴ Bypass surgery is standard treatment for TASC II C-D extensive FP lesions because of its durable patency rate at 5 years of 39% to 52% and 74% to 76% with prosthetic and autogenous vein conduit, respectively.⁴

Although long-term outcomes after EVT for TASC II C-D lesions had been far from satisfactory, recent device improvement has led to better midterm outcomes and widespread use in this setting. In addition, a lower perioperative complications (POCs) rate after EVT compared with bypass surgery supports the current trend. The incidence of POCs after bypass surgery was 21% to 41% (myocardial infarction [MI], 1%-7%; wound infection, 7%-16%; and acute occlusion, 3%-4%),⁵⁻⁷ in contrast with 2% to 17% after EVT (MI, 0%-2%; puncture site complication, 2%-6%; and distal embolization, 1%-2%).⁸⁻¹² In the current era of endovascular predominance, the incidence of 30-day POCs and its effect on long-term clinical outcomes has not been systematically studied. We, therefore, investigated predictors of 30-day POCs after EVT with a provisional stenting strategy for FP lesions and compared prognostic outcomes between patients with and without POCs.

From the Department of Cardiology, Sakakibara Heart Institute, Fuchu^a; the Department of Cardiology, Mie University Graduate School of Medicine, Tsu^b; the Cardiovascular Center, Kansai Rosai Hospital, Amagasaki^c; the Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita^d; the Department of Cardiology, Kokura Memorial Hospital, Kitakyushu^e; the Department of Cardiology, Sendai Kosei Hospital, Sendai^f; and the Department of Cardiology, Matsusaka General Central Hospital, Matsusaka.^g

Author conflict of interest: none.

Reprint requests: Kei Sato, MD, Sakakibara Heart Institute, 3-16-1 Asahichou, Fuchu, Tokyo 183-0003, Japan (e-mail: satokei715@gmail.com).

The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.

0741-5214

Copyright © 2015 by the Society for Vascular Surgery. Published by Elsevier Inc.

<http://dx.doi.org/10.1016/j.jvs.2014.12.051>

METHODS

The protocol for this study was designed according to the Declaration of Helsinki and approved by the Ethics Committee of each participating institution. The protocol was registered with the University Hospital Medical Information Network-Clinical Trial Registry (UMIN000010986). All patients provided written informed consent.

Study population. Data were collected retrospectively from January 2004 to December 2011 in 13 Japanese cardiovascular centers, and 2145 consecutive patients who underwent EVT with provisional stenting strategy for de novo FP disease were finally enrolled for analysis. Exclusion criteria were asymptomatic patients or patients with unknown symptoms before the procedure, restenotic lesions, lesions secondary to a nonatherosclerotic lesion, previous lower extremity bypass surgery or EVT, acute limb ischemia, failed endovascular revascularization, or inadequate data. Independent predictors of 30-day POCs after EVT for FP lesions and the effect of 30-day POCs on prognostic outcomes were assessed.

Interventional procedure. Vascular specialists, including interventional cardiologists, vascular surgeons, and interventional radiologists, decided on the indication for and strategy of the endovascular approach based on computed tomography, duplex ultrasound imaging, or diagnostic angiography. An endovascular-first concept was used in this study.

In most cases, an ipsilateral antegrade or crossover approach was chosen, and a 6F sheath or guiding sheath was inserted through femoral access, followed by 5000 units of unfractionated heparin injection. A 0.035-, 0.018-, or 0.014-inch wire was used based on lesion morphology. If a wire crossing was not successful, especially in totally occlusive lesions, a bidirectional approach was used with distal superficial femoral artery, popliteal artery, or below-the-knee arteries as additional puncture sites to achieve wire crossing.

Balloon angioplasty was performed after wire crossing, and a self-expanding nitinol stent was implanted in cases of flow-limiting dissection or residual stenosis >30%. Stent selection and intravascular ultrasound use was at operator's discretion. Additional balloon angioplasty was done after stent implantation. An Angio-Seal STS Plus closure device (St. Jude Medical, St. Paul, Minn) was used whenever possible.

Dual-antiplatelet therapy with aspirin (100 mg/d) and cilostazol (200 mg/d) or ticlopidine (200 mg/d) was administered to all patients before EVT.

Follow-up was conducted at 1 and 4 weeks and every 3 months thereafter with routine assessment of restenosis by duplex ultrasound imaging and ankle-brachial index (ABI). Target lesion revascularization was planned when symptoms recurred secondary to restenosis or reocclusion.

Definitions. Cardiovascular disease was defined as a history of MI or revascularization or symptomatic status of coronary artery disease or cerebrovascular disease. Critical limb ischemia (CLI) was defined as patients presenting with typical ischemic rest pain or ischemic skin lesions, either ulcer or gangrene. CLI diagnosis was confirmed by ABI with an ankle pressure <50 mm Hg or a toe pressure <30 mm Hg in patients with rest pain; and <70 mm Hg or <50 mm Hg, respectively, in patients with ischemic skin lesions. MI was defined as significant elevation of levels of serum biomarkers (troponin T >0.1 ng/mL or twice normal creatine kinase level). Stroke

was defined as a sustained neurologic deficit confirmed by computed tomography or magnetic resonance imaging. Intestinal bleeding was defined when patients presented bloody stool.

Major adverse cardiovascular events (MACE) included all-cause death, MI, and stroke. Major adverse limb events (MALE) included major amputation or any major reintervention. Major amputation was defined as above-ankle amputation. Surgical reintervention was defined as a surgical procedure (bypass surgery). Any reintervention, including endovascular procedures (balloon angioplasty, atherectomy, stenting) without thrombectomy or thrombolysis in addition to surgical reintervention, was performed only when indicated clinically by symptomatic recurrence. Restenosis was defined as >50% diameter stenosis as determined by angiography or a peak systolic velocity >2.4 m/s.¹³

Outcome measure. The outcome measure of this study was predictors of POCs by logistic regression analysis. We also used the Cox proportional model to assess the effect of POCs on clinical outcomes, including rates of MACE, all-cause death, MI, and stroke, MALE, major amputation, and restenosis.

Statistical analysis. Statistical analysis was performed with SPSS software (SPSS Inc, Chicago, Ill). Descriptive data are reported as means \pm standard deviation for continuous variables or as percentages for dichotomous variables. Between-group differences were evaluated by the unpaired *t*-test for continuous or the Fisher exact test for dichotomous variables. *P* < .05 was considered statistically significant.

Independent predictors of POCs were determined by multivariate logistic regression analysis using three multivariate models for each outcome: model 1 included all variables in the univariate model; model 2 included all significant variables in the univariate model; and model 3 included significant variables in multivariate model 1. The risk of POCs was stratified by the number of risk factors. The Kaplan-Meier method and the Cox proportional hazard regression model were used to analyze the effect of POCs on prognostic outcomes.

RESULTS

POCs. In the overall population, POCs presented \leq 30 days in 209 patients (9.7%; Table 1). Death occurred in 25 patients (1.2%) during the perioperative period: 11 deaths were from infectious death, 5 from cardiac death, 2 from cerebrovascular death, 3 from fatal bleeding, 1 from ischemic colitis, 1 from renal failure, and 2 from unknown reasons. MI, stroke, and intestinal bleeding occurred in 4 (0.2%), 12 (0.6%), and 3 patients (0.1%), respectively. Postprocedural worsening renal function requiring dialysis was documented in one patient (<0.1%). Distal embolism, a limb-threatening complication during EVT, was observed in 22 patients (1.0%). A bidirectional approach was conducted in 305 patients (14%), including popliteal in 256, tibial in 35, and distal superficial femoral artery in 15. Puncture site bleeding complication, which

Download English Version:

<https://daneshyari.com/en/article/2988794>

Download Persian Version:

<https://daneshyari.com/article/2988794>

[Daneshyari.com](https://daneshyari.com)